Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-096674
Filing Date
2025-07-17
Accepted
2025-07-17 17:35:05
Documents
1
Period of Report
2025-07-15

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 6261
  Complete submission text file 0000950170-25-096674.txt   7860
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Issuer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 10026 BROMPTON DRIVE TAMPA FL 33626
Business Address
Jerman Michael Allen (Reporting) CIK: 0001979732 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33038 | Film No.: 251131871